[Allergic Rhinitis and its Impact on Asthma (ARIA) in Latin America].
Allergic rhinitis is the commonest chronic respiratory disorder in children and young adults having an important impact for those suffering this condition, as well as for the public health. Allergic rhinitis is frequently associated to other co-morbidities, particularly asthma and conjunctivitis but, also, sinusitis and otitis media. Most of patients suffering rhinitis are cared by GPs and pediatricians and there are evidences that allergic rhinitis is undertreated, particularly the moderate/severe persistent forms. Clinical guidelines have become an important tool providing recommendations for diagnosis and treatment of different medical conditions. They help the process of decision making for GPs and pediatricians, and many of them, contain an update on basic science and epidemiology. In respiratory medicine, guidelines on asthma and rhinitis are available; however, they do not look at the patients globally and focus the disorder on an organ-specific basis without recommendations on co-morbidities. ARIA, Allergic rhinitis and its impact on asthma, has not been developed only to update specialists in allergy/immunology, otorhinolaryngology and neumology on rhinitis and its comorbidities but, also, to provide recommendations for non-specialists. A new classification and severity of allergic rhinitis is proposed replacing the classic perennial and seasonal forms for persistent and intermittent, mild to moderate/severe. ARIA is an initiative in collaboration with the World Health Organization and the master document has been endorsed by many national and international scientific societies and organizations. ARIA is an evidence-based document also stressing on pediatric aspects and providing recommendations for low-income countries.
Baena-Cagnani
Carlos E
CE
División de inmunología y medicina respiratoria, Departamento de pediatría, Hospital Infantil de Córdoba, Argentina. baena@powernet.net.ar
D000465:Algorithms; D000486:Allergy and Immunology; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D001249:Asthma / Q000191:economics / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D003233:Conjunctivitis, Allergic / Q000209:etiology; D003888:Desensitization, Immunologic; D003906:Developing Countries / Q000191:economics; D019317:Evidence-Based Medicine; D006801:Humans; D007843:Latin America / Q000453:epidemiology; D009938:Organizations; D010033:Otitis Media / Q000209:etiology; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D012221:Rhinitis, Allergic, Perennial / Q000145:classification / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D012852:Sinusitis / Q000150:complications; D012955:Societies, Medical; D014944:World Health Organization / Q000458:organization & administration*
D018927:Anti-Asthmatic Agents